

IN THE COURT OF COMMON PLEAS OF PENNSYLVANIA
PHILADELPHIA COUNTY

IN RE:

YAZ®, YASMIN®, OCELLA® PRODUCT
LIABILITY LITIGATION

SEPTEMBER TERM, 2009
NO. 1307

DOCKETED
COMPLEX LIT CENTER

JUL 7 2011

J. STEWART

CASE MANAGEMENT ORDER NO. 19
(RELATING TO NAME CHANGE FROM BAYER SCHERING PHARMA AG TO BAYER PHARMA AG)

The parties having jointly moved for entry of an Order respecting the fact that, effective July 1, 2011, Bayer Schering Pharma AG has changed its name to Bayer Pharma AG, and to avoid any confusion that may arise as a result of this name change, and good cause appearing,

It is hereby ORDERED as follows:

1. As of July 1, 2011, any and all references to Bayer Schering Pharma AG (or any abbreviation thereof, including "BSP AG" and "BSPAG") contained in this Court's Orders and in any stipulations, pleadings, documents, or registered mailings filed in or related to cases in this litigation shall be construed to reflect the new name of that entity, Bayer Pharma AG. Service may be made on defendant Bayer Pharma AG in the manner prescribed in Case Management Order No. 8. Service made on BSP AG under CMO No. 8 shall continue to constitute valid service on Bayer Pharma AG. This Order also shall apply to all YAZ®/YASMIN®/OCELLA® cases filed in this Court after the date of this Order.

2. Plaintiffs who have named Bayer Schering Pharma AG as a defendant are not required to amend their complaints to reflect that defendant's new name. If a plaintiff files an amended complaint for the sole purpose of incorporating this defendant's new name, the

In Re: Yaz/Yasmin/Ocell-ORDER



09090130700232

defendants that have already filed responsive pleadings are not required to file responsive pleadings to that amended complaint.

3. As of July 1, 2011, the parties are encouraged to refer to this entity as Bayer Pharma AG in all pleadings, documents, registered mailings, and proceedings related to this litigation. Absent an express statement to the contrary, however, any reference to Bayer Schering Pharma AG after July 1, 2011, shall be deemed to refer to Bayer Pharma AG.

Date:

7/7/11


HON. SANDRA MAZER MOSS